Skip to main content
Fresenius SE & Co. KGaA logo

Fresenius SE & Co. KGaA — Investor Relations & Filings

Ticker · FRE ISIN · DE0005785604 LEI · XDFJ0CYCOO1FXRFTQS51 F Human health and social work activities
Open in API
Filings indexed 1,398 across all filing types
Latest filing 2018-09-02 Investor Presentation
Country DE Germany
Listing F FRE

About Fresenius SE & Co. KGaA

https://www.fresenius.com/

Fresenius SE & Co. KGaA is a global healthcare company that provides system-critical products and services for leading therapies for the care of critically and chronically ill patients. The company's portfolio encompasses a wide range of products and services for dialysis, hospitals, and outpatient medical care. Key offerings include intravenously administered generic drugs, biopharmaceuticals, biosimilars, clinical nutrition, and infusion therapies. Additionally, the company operates a large network of private hospitals and outpatient centers. Through its strategic investment in Fresenius Medical Care, it is a leading global provider of products and services for individuals with renal diseases.

Recent filings

Filing Released Lang Actions
Investor Relations General Presentation (englisch)
Investor Presentation Classification · 98% confidence The document is titled "Company Presentation" and contains detailed financial performance data, segment reviews (Fresenius Medical Care, Kabi, Helios, Vamed), forward-looking statements, and specific financial guidance for FY/18 based on H1/18 actuals. The structure, use of slides/tables, and focus on strategy and performance review strongly indicate an Investor Presentation (IP) or a presentation accompanying an earnings release. Since it is a comprehensive presentation detailing performance and outlook, 'Investor Presentation' (IP) is the most accurate classification, rather than just an 'Earnings Release' (ER) which is typically just the highlights announcement.
2018-09-02 German
Release according to Article 41 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled 'Total Voting Rights Announcement' and explicitly mentions the 'Publication of total number of voting rights' as of August 31, 2018. It details a 'Conditional capital increase' and provides the 'New total number of voting rights'. This type of announcement, focusing on the total number of shares/voting rights, is a specific regulatory disclosure. While it relates to capital structure, it is not a general financing update (CAP) or a share issue/change announcement (SHA) in the typical sense of a prospectus or large offering. It is a mandatory disclosure regarding the current voting power structure. Given the options, this specific disclosure about voting rights and capital structure changes fits best under 'Capital/Financing Update' (CAP) as it directly impacts the capital structure, or potentially 'Regulatory Filings' (RNS) if a more specific code isn't available. However, since it details a change related to capital (conditional capital increase) and reports the resulting total voting rights, CAP is the most relevant category among the specific choices provided, as it relates to capital structure changes. If the document were purely about the results of a shareholder vote, DVA would apply, but this is about the total outstanding rights post-measure. Given the focus on the total number of voting rights resulting from a capital measure, CAP is the strongest fit.
2018-08-31 English
Roadshow Brüssel
Investor Presentation Classification · 98% confidence The document is titled '# Roadshow Brussels' and dated '30 August 2018'. It contains detailed financial performance data, segment reviews (Fresenius Medical Care, Kabi, Helios, Vamed), financial outlooks for FY/18, guidance tables, and a 'Financial Review Q2/18' section including a 'Q2 & H1/18 Profit and Loss Statement'. The content structure—a presentation format with slides, market dynamics, and forward-looking statements—is characteristic of an investor presentation or a roadshow presentation designed to communicate recent performance and future strategy to investors. Since it covers half-year results (H1/18) and provides detailed segment analysis, it is more comprehensive than a simple Earnings Release (ER) but less formal and regulatory than a full Interim Report (IR). The best fit among the provided codes for a detailed presentation summarizing interim results and strategy is Investor Presentation (IP).
2018-08-30 English
Commerzbank Sector Conference
Investor Presentation Classification · 98% confidence The document is titled 'Commerzbank Sector Conference Frankfurt' and contains extensive slides detailing the company's (Fresenius) business segments, financial performance (sales, EBIT, margins), market dynamics, and 2018 financial outlook/guidance. The content structure, including slides, charts, and forward-looking statements, is characteristic of an Investor Presentation given at a conference. It is not a formal regulatory filing like a 10-K, nor is it a brief Earnings Release (ER). It is a detailed presentation for investors.
2018-08-28 English
dbAccess European Corporate Days Stockholm
Investor Presentation Classification · 98% confidence The document is titled '# dbAccess European Corporate Days Stockholm' and dated August 23, 2018. It contains detailed financial performance data, segment reviews (Fresenius Medical Care, Kabi, Helios, Vamed), forward-looking statements, and specific guidance/outlook for FY/18 and mid-term targets. The content structure—including slides, segment breakdowns, and financial tables covering sales, EBIT, and net income for Q2/18 and H1/18—is characteristic of an Investor Presentation (IP) or a presentation given at an investor conference. It is not a formal regulatory filing like a 10-K or a brief Earnings Release (ER), but rather a detailed presentation package for investors.
2018-08-23 English
Roadshow Kopenhagen
Investor Presentation Classification · 100% confidence The document is a presentation titled 'Roadshow Copenhagen' dated August 22, 2018. It contains detailed financial performance data, business segment analysis, financial outlooks, and guidance for the Fresenius Group. It is clearly intended for investors to provide information on strategy, market position, and financial results. It fits the definition of an Investor Presentation (IP) as it is a slide deck used for roadshows and investor communication. H2 2018
2018-08-22 English

Browse filings by year

31 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.